ArticleStatistics in medicine2015
A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies.
Article in Statistics in medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- A Novel Method for Inserting Dose Levels Mid-Trial in Early-Phase Oncology Combination Studies.Statistics in medicine · 2026Article
- Isotonic Phase I cancer clinical trial design utilizing patient-reported outcomes.Statistics in biopharmaceutical research · 2025Article
- A new function for drug combination dose finding trials.Scientific reports · 2024Article
- A comparison of model-free phase I dose escalation designs for dual-agent combination therapies.Statistical methods in medical research · 2024Article
- Evaluation of phase I clinical trial designs for combinational agents along with guidance based on simulation studies.Journal of applied statistics · 2023Review
- Practical implementation of the partial ordering continual reassessment method in a Phase I combination-schedule dose-finding trial.Statistics in medicine · 2022Article
- Flexible use of copula-type model for dose-finding in drug combination clinical trials.Biometrics · 2022Article
- A benchmark for dose-finding studies with unknown ordering.Biostatistics (Oxford, England) · 2022Article
- A dose-finding design for dual-agent trials with patient-specific doses for one agent with application to an opiate detoxification trial.Pharmaceutical statistics · 2022Article
- Accuracy and Safety of Novel Designs for Phase I Drug-Combination Oncology Trials.Statistics in biopharmaceutical research · 2022Article
- Adapting isotonic dose-finding to a dynamic set of drug combinations with application to a phase I leukemia trial.Clinical trials (London, England) · 2021Article
- Using an Interaction Parameter in Model-Based Phase I Trials for Combination Treatments? A Simulation Study.International journal of environmental research and public health · 2021Article
- A surface-free design for phase I dual-agent combination trials.Statistical methods in medical research · 2020Article
- CRM2DIM: A SAS macro for implementing the dual-agent Bayesian continual reassessment method.Computer methods and programs in biomedicine · 2019Article
- AAA: triple adaptive Bayesian designs for the identification of optimal dose combinations in dual-agent dose finding trials.Journal of the Royal Statistical Society. Series C, Applied statistics · 2019Article
- The Impact of Early-Phase Trial Design in the Drug Development Process.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- How to design a dose-finding study on combined agents: Choice of design and development of R functions.PloS one · 2019Article
- Revisiting isotonic phase I design in the era of model-assisted dose-finding.Clinical trials (London, England) · 2018Article
- Designs for phase I trials in ordered groups.Statistics in medicine · 2017Article
- Practical designs for Phase I combination studies in oncology.Journal of biopharmaceutical statistics · 2016Review
Corrections and comments
- Commented on by
- Commented on byAuthors' Reply.2016
Authors and funding
4 authors.
Funding
Abstract
Little is known about the relative performance of competing model-based dose-finding methods for combination phase I trials. In this study, we focused on five model-based dose-finding methods that have been recently developed. We compared the recommendation rates for true maximum-tolerated dose combinations (MTDCs) and over-dose combinations among these methods under 16 scenarios for 3 × 3, 4 × 4, 2 × 4, and 3 × 5 dose combination matrices. We found that performance of the model-based dose-finding methods varied depending on (1) whether the dose combination matrix is square or not; (2) whether the true MTDCs exist within the same group along the diagonals of the dose combination matrix; and (3) the number of true MTDCs. We discuss the details of the operating characteristics and the advantages and disadvantages of the five methods compared.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.